Ambalal Sarabhai Enterprises Ltd
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics[1]
- Market Cap ₹ 210 Cr.
- Current Price ₹ 27.4
- High / Low ₹ 53.8 / 26.0
- Stock P/E 22.3
- Book Value ₹ 7.17
- Dividend Yield 0.00 %
- ROCE 6.01 %
- ROE 6.80 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.83 times its book value
- Promoter holding is low: 31.4%
- Tax rate seems low
- Company has a low return on equity of 8.72% over last 3 years.
- Earnings include an other income of Rs.17.1 Cr.
- Working capital days have increased from -538 days to 109 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.67 | 15.25 | 6.98 | 1.51 | 0.92 | 0.00 | 0.00 | 0.00 | 0.13 | 3.71 | 3.81 | 4.04 | 5.33 | |
| 29.02 | 27.30 | 28.62 | 14.47 | 21.76 | 8.86 | 7.86 | 11.69 | 5.71 | 8.87 | 8.61 | 11.37 | 12.43 | |
| Operating Profit | -13.35 | -12.05 | -21.64 | -12.96 | -20.84 | -8.86 | -7.86 | -11.69 | -5.58 | -5.16 | -4.80 | -7.33 | -7.10 |
| OPM % | -85.19% | -79.02% | -310.03% | -858.28% | -2,265.22% | -4,292.31% | -139.08% | -125.98% | -181.44% | -133.21% | |||
| 3.43 | 14.17 | 95.94 | -0.63 | 24.49 | 6.46 | 24.61 | 3.16 | 9.47 | 9.75 | 7.89 | 15.85 | 17.13 | |
| Interest | 9.12 | 7.91 | 1.99 | 2.62 | 1.05 | 0.62 | 0.46 | 0.56 | 0.25 | 0.11 | 2.16 | 0.34 | 0.30 |
| Depreciation | 1.52 | 3.36 | 14.62 | 2.45 | 0.42 | 0.40 | 0.39 | 0.38 | 0.19 | 0.15 | 0.12 | 0.10 | 0.08 |
| Profit before tax | -20.56 | -9.15 | 57.69 | -18.66 | 2.18 | -3.42 | 15.90 | -9.47 | 3.45 | 4.33 | 0.81 | 8.08 | 9.65 |
| Tax % | 0.00% | 0.00% | 20.80% | 10.18% | 166.06% | 13.45% | 2.20% | -0.84% | 14.49% | 5.31% | -217.28% | -1.98% | |
| -20.57 | -9.15 | 45.68 | -20.57 | -1.44 | -3.88 | 15.55 | -9.39 | 2.96 | 4.11 | 2.58 | 8.24 | 9.97 | |
| EPS in Rs | -2.68 | -1.19 | 5.96 | -2.68 | -0.19 | -0.51 | 2.03 | -1.23 | 0.39 | 0.54 | 0.34 | 1.08 | 1.30 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | % |
| 3 Years: | 214% |
| TTM: | 117% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -28% |
| 3 Years: | -4% |
| TTM: | 7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 4% |
| 3 Years: | 1% |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | 6% |
| 3 Years: | 9% |
| Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 |
| Reserves | -64.34 | -73.49 | -27.80 | -46.41 | -47.98 | -51.85 | -36.39 | -45.85 | -42.93 | -38.79 | -36.34 | -28.14 | -21.66 |
| 27.27 | 30.10 | 29.54 | 22.13 | 11.07 | 11.07 | 11.00 | 11.14 | 9.77 | 11.49 | 10.03 | 7.66 | 8.76 | |
| 97.45 | 103.24 | 65.13 | 63.81 | 91.28 | 102.78 | 73.35 | 58.14 | 39.53 | 30.42 | 30.96 | 26.77 | 19.14 | |
| Total Liabilities | 137.01 | 136.48 | 143.50 | 116.16 | 131.00 | 138.63 | 124.59 | 100.06 | 83.00 | 79.75 | 81.28 | 82.92 | 82.87 |
| 46.41 | 42.66 | 20.60 | 16.43 | 14.98 | 14.65 | 14.48 | 13.97 | 13.00 | 12.86 | 12.84 | 12.22 | 12.18 | |
| CWIP | 0.10 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 56.16 | 56.29 | 82.91 | 76.19 | 55.88 | 55.97 | 56.43 | 26.58 | 25.54 | 25.54 | 25.39 | 25.34 | 25.34 |
| 34.34 | 37.43 | 39.99 | 23.54 | 60.14 | 68.01 | 53.68 | 59.51 | 44.46 | 41.35 | 43.05 | 45.36 | 45.35 | |
| Total Assets | 137.01 | 136.48 | 143.50 | 116.16 | 131.00 | 138.63 | 124.59 | 100.06 | 83.00 | 79.75 | 81.28 | 82.92 | 82.87 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.43 | -12.05 | -69.37 | -3.67 | -12.66 | -3.27 | -4.53 | -10.42 | -7.79 | 1.52 | -3.82 | -4.08 | |
| 2.34 | 12.70 | 75.22 | 8.64 | 26.14 | 2.37 | 4.92 | 15.76 | 20.77 | 0.61 | 3.48 | 6.35 | |
| -4.00 | -0.75 | -2.56 | -8.14 | -12.15 | -0.44 | -0.42 | -0.32 | -16.46 | -3.76 | 0.30 | -2.31 | |
| Net Cash Flow | -0.23 | -0.10 | 3.30 | -3.17 | 1.33 | -1.33 | -0.03 | 5.02 | -3.47 | -1.63 | -0.04 | -0.04 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 78.26 | 37.34 | 1.57 | 0.00 | 0.00 | 421.15 | 29.51 | 37.36 | 37.04 | |||
| Inventory Days | 5.63 | 76.36 | 22.52 | 47.93 | 56.64 | 0.00 | 2.01 | 0.00 | 0.00 | |||
| Days Payable | 391.01 | 320.68 | 729.22 | 3,974.44 | 13,253.28 | 1,611.83 | ||||||
| Cash Conversion Cycle | -307.12 | -206.97 | -705.13 | -3,926.52 | -13,196.64 | 421.15 | -1,580.31 | 37.36 | 37.04 | |||
| Working Capital Days | -2,072.60 | -2,355.15 | -3,035.57 | -16,105.93 | -23,784.51 | -30,660.00 | -1,037.94 | -686.89 | 109.32 | |||
| ROCE % | -22.31% | -34.09% | -59.62% | -12.82% | -21.98% | -7.41% | 36.90% | -4.27% | 9.93% | 11.12% | 5.96% | 6.01% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5 Jan - Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018. Kindly take the same on your records.
- Closure of Trading Window 31 Dec
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov 2025 - Newspaper publication under regulation 30 and 47 of SEBI (LODR) Regulation, 2015. Kindly take the same on your records.
-
Results For The Quarter And Half Year Ended 30.09.2025
12 Nov 2025 - Approved unaudited consolidated and standalone Q2/H1 results to Sept 30, 2025; consolidated H1 PAT Rs 766.32 lakhs
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 12.11.2025
12 Nov 2025 - Board approved Q2/H1 results (30 Sep 2025): H1 consolidated profit Rs766.32 lakh; Q2 loss Rs56.03 lakh.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
ASE is a pharmaceutical health care companies, which through its group companies, manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and abroad